Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $112
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has maintained an Outperform rating on Axsome Therapeutics (NASDAQ:AXSM) and increased the price target from $108 to $112.
May 07, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Joel Beatty reaffirmed an Outperform rating on Axsome Therapeutics and raised the price target from $108 to $112.
The increase in price target by Baird reflects a positive outlook on Axsome Therapeutics, suggesting confidence in the company's future performance. This analyst action can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100